First Immune-Modulating Drug Trial Targets Neuroinflammation in Prodromal Parkinson’s Disease
A published protocol details the first randomised, placebo-controlled trial testing whether the oral drug PXS-4728A reduces PET-measured brain neuroinflammation in ...
